Visterra, Inc.

Massachusetts Institute of Technology

University of California

University of Massachusetts

The Charles Stark Draper Laboratory, Inc.

Momenta Pharmaceuticals, Inc.

Karthik Viswanathan

Zachary Shriver

Boopathy Ramakrishnan

Andrew M Wollacott

Gregory Babcock

James R Myette

Ram Sasisekharan

Vidya Subramanian

Hedy Adari-Hall

Rahul Raman

Brian Booth

Luke Nathaniel Robinson

Sasisekharan Raguram

Viswanathan Sasisekharan

S Raguram

Venkataramanan Soundararajan

Aarthi Chandrasekaran

Obadiah Joseph Plante

Lauren Olinski

James C Delaney

Aravind Srinivasan

Akila Jayaraman

Bharat Chaganty

Xiaoying Koh

Carlos J Bosques

Kannan Tharakaraman

Robert W Finberg

Nishla Keiser

James Constantine Comolli

Susan Sloan

Nathan Wilson Stebbins

Sasi Raguram

Pankaj Gandhe

Kristin Narayan

Jose Trevejo

Deborah Fygenson

Kai Li

Tyree J Koch

Kenneth Douglas Johnson

Hamid Tissire

Jose Miguel Trevejo

Maciej Boni

Jennifer Wang

Zachary Holmes Shriver

Zachary H Shriver

Luke Robinson

James Myette

Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

Antibody molecules to C5AR1 and uses thereof

Humanized antibody molecules that specifically bind to CD138 are disclosed. The humanized antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.

Humanized antibody molecules to CD138 and uses thereof

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Humanized complement 5a receptor 1 antibodies and methods of use thereof

Humanized complement 5A receptor 1 antibodies and methods of use thereof

Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL)

Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.

Antibody molecules to dengue virus and uses thereof

This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.

Ha binding agents

Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

Antibody molecule-drug conjugates and uses thereof

Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.

Antibody molecules to CD138 and uses thereof

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

Engineered polypeptides and uses thereof

Antibody molecules to C5aR1 and uses thereof

Growing community of inventors

Waltham, MA, United States of America

Karthik Viswanathan